Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00089440
Verified July 2005 by National Institute on Drug Abuse (NIDA). Recruitment status was: Active, not recruiting
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.
Condition or disease
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.